LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to slow or stop the progression of HD Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause […]
Caroline reflected on her journey and motivations in becoming a scientist and researcher, and what fuelled her passion to focus on Huntington’s disease and eventually co-founding LoQus23 Therapeutics with CEO David Reynolds. She also delves into the disease pathology and genetic basis of Huntington’s disease – a devastating disease for which there is currently no […]
Dr Mozayeni brings deep experience in biotech corporate strategy and business development Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington’s disease into the clinic Cambridge, UK, 18 February 2025 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs […]
Our CEO David Reynolds spoke with Amy Brown from BiotechTV on LoQus23’s unique approach to Huntington’s disease, investigating small molecule drugs that could stop DNA instability and slow neurodegeneration. Watch video
Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially disease-modifying therapy for Huntington’s disease Forbion General Partner Rogier Rooswinkel joins Board of Directors […]
CHENGDU, China, July 27, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company discovering small molecule therapies that target aberrant DNA damage repair to treat Huntington’s disease and other triplet repeat diseases (TRDs). HitGen […]
Researchers at three universities in Ireland, Scotland and Wales are joining forces to develop new tools for identifying drugs to treat multiple, currently incurable, neurological diseases. In this new project, the three teams will work together to develop novel technologies to monitor how the number of repeats changes in cells grown in the laboratory. This […]
Dr Ivarsson is currently Chief Development Officer at Moderna and led clinical trials of the company’s Covid-19 vaccine Cambridge, UK – 25th January 2022 – LoQus23 Therapeutics Ltd. (‘LoQus23’), a biotech discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington’s and other triplet repeat diseases, announces the appointment of Dr […]
Company targets DNA mismatch repair pathways to slow neurodegeneration in Huntington’s Disease and other triplet repeat disorders LoQus23’s structure-based approach focuses on oral small molecule drugs Cambridge, UK – 23rd November 2021 – LoQus23 Therapeutics Ltd. (‘LoQus23’), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington’s and other […]
Dr Caroline Benn (CSO of LoQus23) and Dr Ricardo Mouro Pinto (Massachusetts General Hospital) are co-recipients of a Friedreich’s Ataxia Research Alliance grant (supported by the Crisp Family Fund). Like Huntington’s disease, Friedreich’s ataxia (FA) is a trinucleotide repeat expansion disease that has somatic instability – but understanding of how this instability contributes to disease progression […]
